Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Still, companies prescribing compounded GLP-1s now seem to be trying to justify the prescriptions based on compounding’s second purpose: a need for customized versions of the drugs.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

One-year plans for compounded semaglutide cost $165 a month, he said. Hims & Hers will continue to sell customized versions of semaglutide for those prescribed it, a company spokesman said later ...

For compounded tirzepatide, Burch’s pharmacy charges between $200 and $400 a month, based on the dose. Without insurance, Mounjaro costs $1,069 per month, and Zepbound is $1,060, according to Lilly.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the ...

Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival ...